Trial Profile
A Randomized, Open-Label Phase IIb Trial of Maintenance Therapy With a MUC1 Dendritic Cell Vaccine (CVac) for Epithelial Ovarian Cancer Patients in First or Second Remission
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cancer vaccine MUC-1 (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Immutep Limited; Prima BioMed
- 28 Nov 2017 According to a Prima BioMed media release, Prima BioMed changed its name to Immutep Limited.
- 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 21 May 2015 Results of overall survival analysis in second remission patients published in a Prima BioMed media release.